Vaccines against Group B Coxsackieviruses and Their Importance

Kiruthiga Mone, University of Nebraska - Lincoln
Ninaad Lasrado, University of Nebraska-Lincoln
Meghna Sur, University of Nebraska-Lincoln
Jay Reddy, University of Nebraska - Lincoln

Document Type Article

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

Abstract

The group B coxsackieviruses (CVBs) exist in six serotypes (CVB1 to CVB6). Disease associations have been reported for most serotypes, and multiple serotypes can cause similar diseases. For example, CVB1, CVB3, and CVB5 are generally implicated in the causation of myocarditis, whereas CVB1 and CVB4 could accelerate the development of type 1 diabetes (T1D). Yet, no vaccines against these viruses are currently available. In this review, we have analyzed the attributes of experimentally tested vaccines and discussed their merits and demerits or limitations, as well as their impact in preventing infections, most importantly myocarditis and T1D.